Logo image of RNAZ

TRANSCODE THERAPEUTICS INC (RNAZ) Stock Fundamental Analysis

NASDAQ:RNAZ - Nasdaq - US89357L4023 - Common Stock - Currency: USD

7.37  -0.13 (-1.73%)

Fundamental Rating

3

Overall RNAZ gets a fundamental rating of 3 out of 10. We evaluated RNAZ against 559 industry peers in the Biotechnology industry. RNAZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RNAZ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RNAZ has reported negative net income.
RNAZ had a negative operating cash flow in the past year.
RNAZ had negative earnings in each of the past 5 years.
RNAZ had a negative operating cash flow in each of the past 5 years.
RNAZ Yearly Net Income VS EBIT VS OCF VS FCFRNAZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -193.60%, RNAZ is doing worse than 88.55% of the companies in the same industry.
RNAZ's Return On Equity of -248.18% is on the low side compared to the rest of the industry. RNAZ is outperformed by 70.48% of its industry peers.
Industry RankSector Rank
ROA -193.6%
ROE -248.18%
ROIC N/A
ROA(3y)-273.44%
ROA(5y)-214.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAZ Yearly ROA, ROE, ROICRNAZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

RNAZ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAZ Yearly Profit, Operating, Gross MarginsRNAZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for RNAZ has been increased compared to 1 year ago.
Compared to 5 years ago, RNAZ has more shares outstanding
There is no outstanding debt for RNAZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNAZ Yearly Shares OutstandingRNAZ Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
RNAZ Yearly Total Debt VS Total AssetsRNAZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -9.63, we must say that RNAZ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.63, RNAZ is doing worse than 72.99% of the companies in the same industry.
RNAZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.63
ROIC/WACCN/A
WACCN/A
RNAZ Yearly LT Debt VS Equity VS FCFRNAZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

RNAZ has a Current Ratio of 5.20. This indicates that RNAZ is financially healthy and has no problem in meeting its short term obligations.
RNAZ has a Current ratio of 5.20. This is comparable to the rest of the industry: RNAZ outperforms 54.38% of its industry peers.
A Quick Ratio of 5.20 indicates that RNAZ has no problem at all paying its short term obligations.
RNAZ has a Quick ratio of 5.20. This is comparable to the rest of the industry: RNAZ outperforms 55.46% of its industry peers.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
RNAZ Yearly Current Assets VS Current LiabilitesRNAZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.31% over the past year.
EPS 1Y (TTM)99.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RNAZ will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
Based on estimates for the next years, RNAZ will show a very strong growth in Revenue. The Revenue will grow by 147.39% on average per year.
EPS Next Y99.7%
EPS Next 2Y41.41%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.39%

3.3 Evolution

RNAZ Yearly Revenue VS EstimatesRNAZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2028 2029 2030 10M 20M 30M 40M 50M
RNAZ Yearly EPS VS EstimatesRNAZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -200K -400K -600K -800K -1M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RNAZ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNAZ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAZ Price Earnings VS Forward Price EarningsRNAZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAZ Per share dataRNAZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K

4.3 Compensation for Growth

A more expensive valuation may be justified as RNAZ's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.41%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNAZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSCODE THERAPEUTICS INC

NASDAQ:RNAZ (6/10/2025, 8:06:03 PM)

7.37

-0.13 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2025-04-15/amc
Earnings (Next)N/A N/A
Inst Owners21.41%
Inst Owner Change21380.8%
Ins Owners0.01%
Ins Owner Change0%
Market Cap6.12M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-1462.72
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-15.08
FCFYN/A
OCF(TTM)-15.05
OCFYN/A
SpS0
BVpS12.4
TBVpS12.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -193.6%
ROE -248.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-273.44%
ROA(5y)-214.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z -9.63
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)45.08%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.58%
EPS Next Y99.7%
EPS Next 2Y41.41%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.39%
EBIT growth 1Y12.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.47%
OCF growth 3YN/A
OCF growth 5YN/A